Thrombin inhibition profiles in healthy individuals and thrombophilic patients

• DOI: 10.1160/th11-10-0719
• Publication Date: 2012-01-25T07:05:36Z
• Authors: Ursula Harbrecht; Rolf Fimmers; Johannes Oldenburg; Günter Mayer; Heiko Rühl; Jens Müller; Bernd Pötzsch
• Keywords: Direct thrombin inhibitor

Summary Inhibition of thrombin by endogenous inhibitors plays a central role in the spatiotemporal control clot formation. A failure to adequately inactivate such as antithrombin deficiency generates strong prothrombotic phenotype. To study if and what extent delayed inactivation rates beyond contribute phenotype we measured inhibition profiles plasma samples obtained from 16 healthy individuals 39 thrombophilic patients, including 17 patients diagnosed positive for anti-prothrombin/phospholipid antibodies. test inhibition, was added plasma, stopped addition reversible inhibitor argatroban. Subsequently, amount argatroban-complexed using an oligonucleotide-based enzyme capture assay. In normal human at concentrations up 4 ng/ml (109 pM) became inactivated with average half-life time 56.4 ± 4.7 seconds (s). antithrombin-deficient prolonged 168.2 14.9 s. Among only one mild showed impaired rates, whereas all other antiphospholipid inhibiting capacities within range. We conclude that subthreshold levels ∼100 pM or below becomes 1 minute. Antiphospholipid antibodies do not prolong times, making it unlikely contributes thrombotic syndrome. contrast, falling 80% markedly half-life.